{"nctId":"NCT01181141","briefTitle":"Study of DU-176b, Prevention of Venous Thromboembolism in Patients After Hip Fracture Surgery","startDateStruct":{"date":"2008-10"},"conditions":["Venous Thromboembolism"],"count":92,"armGroups":[{"label":"DU-176b","type":"EXPERIMENTAL","interventionNames":["Drug: DU-176b (edoxaban)"]},{"label":"Enoxaparin sodium","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Enoxaparin sodium 20mg"]}],"interventions":[{"name":"DU-176b (edoxaban)","otherNames":[]},{"name":"Enoxaparin sodium 20mg","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Subjects who are scheduled to undergo surgery within 10 days for fracture of inner or outer femoral neck (trochanteric and subtrochanteric)\n\nExclusion Criteria:\n\n* Subjects with risks of hemorrhage\n* Subjects with thrombolic risks\n* Subjects who weigh less than 40 kg\n* Subjects who are pregnant or suspect pregnancy, or subjects who want to become pregnant","healthyVolunteers":false,"sex":"ALL","minimumAge":"20 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"The Incidence of Major or Clinically Relevant Non-major Bleeding","description":"Bleeding events during the period from the start of treatment with the study drug (study treatment) to the day of the follow-up examination were assessed as the primary endpoints.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.4","spread":null},{"groupId":"OG001","value":"6.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Proportion of Subjects With Venous Thromboembolism Events.","description":null,"paramType":null,"dispersionType":null,"classes":[]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":3,"n":59},"commonTop":["blood urine present","urinary tract infection","Aspartate aminotransferase increased","diarrhea","cystitis"]}}}